jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Oct. 15, 2020

Jan. 20, 2021

jRCT2031200156

Phase 2 study of BK1304 in healthy children

Phase 2 study of BK1304 in healthy children

Fuji Hideyuki

The Research Foundation for Microbial Diseases of Osaka University

3-1, Yamada-oka, Suita, Osaka

pivotal@mail.biken.or.jp

Fuji Hideyuki

The Research Foundation for Microbial Diseases of Osaka University

3-1, Yamada-oka, Suita, Osaka

pivotal@mail.biken.or.jp

Complete

Oct. 01, 2020

Oct. 01, 2020
120

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

prevention purpose

A person who has written informed consent from legal guardian and has obtained an ascent from subject

History of influenza virus infection or influenza vaccination within 180 days prior to the first dose of study drug
History of anaphylaxis to food or drug
Judged ineligible for the study by investigator

6age old over
13age old not

Both

Prevention of influenza

injection of Investigational new drug

Response rate, geometric mean titer and geometric mean titer increase of nasal IgA antibody.
Geometric mean titer of nasal neutralizing antibody.
Seroconversion rate, seroprotection rate, geometric mean titer and geometric mean titer increase of serum HI antibody.
Adverse events and adverse reactions.

The Research Foundation for Microbial Diseases of Osaka University
Sugiura Clinic Institutional Review Board
4-4-16-301, Hon-cho, Kawaguchi-City, Saitama
Approval

Sept. 03, 2020

No

none

History of Changes

No Publication date
2 Jan. 20, 2021 (this page) Changes
1 Oct. 15, 2020 Detail